(Q38125240)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

title

Update on the use of abatacept for the treatment of rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference

Gabriel Herrero-Beaumont

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

author name string

Esther F Vicente Rabaneda

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

Santos Castañeda

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

publication date

1 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Clinical Immunology

6 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

page(s)

599-621

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

Severe functional declines, work disability, and increased mortality in seventy-five rheumatoid arthritis patients studied over nine years

6 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

The prevalence of rheumatoid arthritis in the general population of Spain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Methotrexate--how does it really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Therapeutic strategies for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Rheumatoid arthritis therapy: advances from bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Treating rheumatoid arthritis to target: recommendations of an international task force

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

CTLA4Ig: a novel inhibitor of costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

CTLA-4 is a second receptor for the B cell activation antigen B7

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Abatacept, a novel CD80/86-CD28 T cell co-stimulation modulator, in the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Advances in CTLA-4-Ig-mediated modulation of inflammatory cell and immune response activation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Treatment of murine lupus with CTLA4Ig

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Abatacept treatment for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Longterm safety and efficacy of abatacept through 5 years of treatment in patients with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Sustained disease remission and inhibition of radiographic progression in methotrexate-naive patients with rheumatoid arthritis and poor prognostic factors treated with abatacept: 2-year outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Immunogenicity, safety, and efficacy of abatacept administered subcutaneously with or without background methotrexate in patients with rheumatoid arthritis: results from a phase III, international, multicenter, parallel-arm, open-label study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Comparative effectiveness and safety of biological treatment options after tumour necrosis factor α inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Abatacept for rheumatoid arthritis: a Cochrane systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Infections requiring hospitalization in the abatacept clinical development program: an epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Malignancies in the rheumatoid arthritis abatacept clinical development programme: an epidemiological assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Non-infectious pulmonary complications of newer biological agents for rheumatic diseases--a systematic literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Vaccination response to tetanus toxoid and 23-valent pneumococcal vaccines following administration of a single dose of abatacept: a randomized, open-label, parallel group study in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

Epidemiology and burden of illness of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F1744666X.2013.811192

10.1586/1744666X.2013.811192

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23899231%20AND%20SRC:MED&resulttype=core&format=json

6 March 2020

1 reference